Form 4: RA Capital Buys Artiva Biotherapeutics Shares

RA Capital Management and affiliated entities report significant purchases of Artiva Biotherapeutics common stock, increasing their beneficial ownership.

Summary

• RA Capital Management, L.P., along with several affiliated funds (RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus III, L.P.) and individuals Peter Kolchinsky and Rajeev Shah, have reported transactions involving Artiva Biotherapeutics, Inc. (ARTV).
• On June 25, 2026, RA Capital Management acquired 31,000 shares of common stock at a weighted average price of $8.88, with individual transaction prices ranging from $8.62 to $8.98.
• On June 26, 2026, an additional 1,876 shares were acquired at a weighted average price of $8.98, with prices ranging from $8.97 to $9.00.
• Following these transactions, the total beneficial ownership held indirectly by RA Capital Management and its affiliates amounts to 16,795,919 shares.
• Additional holdings of 264,571, 826,832, and 68,320 shares are held directly by RA Capital Nexus Fund, L.P., RA Capital Nexus III, L.P., and a separately managed account, respectively.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to significant stock purchases by a major investor, indicating confidence, though the lack of operational or financial data limits a higher score.

Positives

• Significant stock purchases by a major investor (RA Capital Management) indicate confidence in the company's future prospects.
• The reporting persons are identified as both a Director and a 10% Owner, suggesting a substantial and involved stake in the company.
• The weighted average pricing for the purchases suggests strategic acquisition over a period, potentially optimizing entry price.

Negatives

• The filing is a Form 4, which reports changes in beneficial ownership and does not contain financial performance data or forward-looking guidance, thus limiting the assessment of company performance.
• The nature of the transactions (purchases) does not inherently signal negative performance, but the lack of context on the company's operational status is a limitation.

Risks

• The filing does not explicitly mention any risks. However, as a Form 4, it is a disclosure of ownership changes and not a risk assessment document.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reporting persons (RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus III, L.P., Peter Kolchinsky, and Rajeev Shah) disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.
• Laura Stoppel, a Principal of RA Capital Management, serves on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that significant stake-building by institutional investors like RA Capital Management in biotechnology companies is common, often signaling conviction in the company's pipeline or technology. However, without more context on Artiva Biotherapeutics' specific stage of development or recent news, it's difficult to assess the broader industry implications.

Stakeholder Impact

• Shareholders may view the increased stake by a significant investor as a positive signal, potentially leading to increased confidence and share price appreciation.
• Management and employees may see this as validation of their strategy and efforts.
• Creditors and suppliers are unlikely to be directly impacted by this ownership change, but a stable or growing shareholder base can indirectly support the company's financial stability.

Next Steps

• Continued monitoring of RA Capital Management's beneficial ownership and any subsequent filings.
• Further analysis of Artiva Biotherapeutics' operational and financial performance to understand the strategic rationale behind the investment.

Key Dates

Recommendation

The filing indicates increased confidence from a major investor, which is positive. However, as a Form 4, it lacks the financial and operational details necessary to make a strong buy or sell recommendation. Therefore, a 'hold' recommendation is appropriate pending further information on the company's performance and strategy.

Keywords

Form 4, SEC Filing, Beneficial Ownership, RA Capital Management, Artiva Biotherapeutics, ARTV, Stock Purchase, Insider Trading, 10% Owner, Director